




22 23 b ,  
 2 20 T ,  
 C ( ) ,  
 27 30 ,  
 b b b b  
 2 5 ,  
 2 .  
*S. sarmentosum*  
*S. sarmentosum*  
*in vitro in vivo.*



### Results and Discussion.

b b b b b b  
 31 T  
 b b b b b b  
 32 33 A T  
 b b b b b b  
*in vitro in vivo,* -7-O- $\beta$ -D-  
 (1),  
 B




Tricin-7-O- $\beta$ -D-glucopyranoside (1)  
 (Glc =  $\beta$ -D-glucopyranosyl)


1. Effect of EESS on Splenocyte Proliferation and  
 T- B-  
 b b b b b b




1. Effect of the EtOH extract of *...* (SI; *Exper. Part*).  $\pm$  S.E. (n = 4).  
 \*:  $p < 0.05$ , \*\*:  $p < 0.01$ , \*\*\*:  $p < 0.001$ . C A: *...*

2. Effect of EESS on the OVA-Specific Serum Antibody Response in OVA-Immunized Mice.







2. Dose-dependent inhibitory effect of the EtOH extract of *Trigonotis henryi* (C) on OVA- or mitogen-stimulated splenocyte proliferation in OVA-immunized mice. C (Control), A (CsA), 0 (0.1 mg), 14 (0.25 mg), 5 (0.5 mg), 7 (1.0 mg), 1 (0.1 mg), 2 (0.25 mg), 3 (0.5 mg), 4 (1.0 mg). (SI; Exper. Part).  $\pm$  (n 5). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ; C A :  $p < 0.05$ , :  $p < 0.01$ , :  $p < 0.001$ .





3. Dose-dependent inhibitory effect of the EtOH extract of *Trigonotis henryi* (C) on OVA-specific IgG, IgG1, and IgG2b antibodies in OVA-immunized mice. C (Control), A (CsA), 0 (0.1 mg), 14 (0.25 mg), 5 (0.5 mg), 7 (1.0 mg), 1 (0.1 mg), 2 (0.25 mg), 3 (0.5 mg), 4 (1.0 mg). (Absorbance<sub>492nm</sub>; Exper. Part).  $\pm$  (n 5). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ; C A :  $p < 0.05$ , :  $p < 0.01$ , :  $p < 0.001$ .





### 3. Immunosuppressive Activity of Four Fractions of EESS.





#### 4. Effect of the EtOH extract of *...* ( ), and its fractions on Con A- and OVA-stimulated splenocyte proliferation in OVA-immunized mice.






Fig. 5. Effect of the EtOH extract of *Trigonotis borealis* (T. borealis), and its fractions on OVA-specific IgG, IgG1, and IgG2b antibodies in OVA-immunized mice. C

Control (C), 0.25, 0.5, 1.0 mg of EtOH extract (E), and its fractions (A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z). The results are expressed as mean  $\pm$  SD (n = 5). Statistical significance was determined by one-way ANOVA. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001; A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z. Part of the results are shown in Table 1. A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z. Exper.

in vitro 39. T<sub>1</sub>, 1. T<sub>2</sub> B-  
 3.44±0.05%.  
 in vitro in vivo  
*S. sarmentosum*.

### Conclusions.

in vitro, C A-  
 A- A B  
*S. sarmentosum*

### Experimental Part

General. (A), 3-(4,5-  
 (TT), A(C A), -2-)-2,5-  
 -1640  
 Sigma Chemical Co. (A),  
 Southern Biotech. Assoc. (B  
 Hangzhou Sijiqing Corp.,  
 Zhejiang Wanma Pharm Co. Ltd, A(C A,  
 Hangzhou Huadong Medicine Co. Ltd,

### Experimental Animals.

Zhejiang Experimental Animal Center (C  
 22-2001001, ad libitum,  
 24±1°, 50±10%, 12/12  
 Institute for Experimental Animals

### Plant Material.

*Sedum sarmentosum* BUNGE  
 2004. A (20040612)

### Laboratory of Nature Drug, C

### Xiang-Ji Xue

### Preparation and Analysis of Extract.

*S. sarmentosum* 40°  
 70%  
 (1700×g, 30),  
 45°  
 5.24% (w/w)).  
 (A, B,  
 0.22-μm Millipore  
 Symmetry® C18 (250 ×  
 Waters 2996 PDA  
 Water 600E  
 A 10 /  
 0.22-μm Millipore  
 0.89% T<sub>1</sub>



*Limulus* (Zhejiang A and C Biological, C). T  
 0.5 ( )/  
*Splenocyte Proliferation Assay.* Hank  
 (Sigma),  
 (1500 × g 4° 10 ), 1640 12 M HEPES (7.1), 0.05 M 2-  
 100 / 100 μ / 10% C ). C 95%.  
 28 . B 96-  
 (Nunc) 1 × 10<sup>7</sup> / 100 μ C A  
 5 μ / ), ( 10 μ / ), 1640 C A  
 ( 0.1 100.0 μ / ) 200 μ ( TT  
 37° 5% C<sub>2</sub> A 44 50 μ (1400 ×  
 (2 / ) 4 TT  
 g, 5 ), 8 μ 1 C ) 200 μ  
 (192 μ 570 630- 15 T (SI)  
 b b SI b b  
*Administration and Immunization.* T 28 .  
 C b b 200 μ A 1 Alum 0.2  
 0. A b 2 B 0.25, 0.5,  
 1.0 ( ) 0.1 0.2 A (C A  
 T T  
 A-  
*Splenocyte Proliferation Assay.*  
 96- (Nunc) 1 × 10

Statistical Analysis. T Student's t-test,  $p < 0.05$

2004 13 1360002) Zhejiang Provincial Science and Technology Council (

## C

- 1 . . . . ., *J. Tradit. Chin. Vet. Med.* **2006**, 6, 33.
- 2 A. . . . ., *Phytochemistry* **1998**, 49, 2607.
- 3 . . . . ., *Lishizhen Med. Mater. Med. Res.* **2001**, 12, 888.
- 4 . . . . ., *Lishizhen Med. Mater. Med. Res.* **2002**, 13, 714.
- 5 . . . . ., *Chem. Pharm. Bull.* **2007**, 55, 1185.
- 6 . . . . ., *Chin. J. Microbiol. Immunol.* **1982**, 1, 145.
- 7 . . . . ., *Pharmacol. Clin. Chin. Mater. Med.* **1995**, 5, 30.
- 8 . . . . ., *Pharmacol. Clin. Chin. Mater. Med.* **2000**, 16, 19.
- 9 B. . . . ., *Pharmacol. Clin. Chin. Mater. Med.* **2001**, 12, 430.
- 10 T. . . . ., *J. Ethnopharmacol.* **2000**, 70, 177.
- 11 . . . . ., *J. Nutr. Sci. Vitaminol.* **2004**, 50, 100.
- 12 . . . . ., *Biol. Pharm. Bull.* **2004**, 27, 2035.
- 13 . . . . ., *Food Sci.* **2006**, 27, 89.
- 14 . . . . ., A. B. . . . ., *Phytochemistry* **1996**, 41, 503.
- 15 A. . . . ., *Chin. Tradit. Herb. Drugs* **1997**, 28, 517.
- 16 . . . . ., *Chin. Tradit. Herb. Drugs* **2001**, 32, 305.
- 17 T. . . . ., *J. Beijing Univ. Tradit. Chin. Med.* **2003**, 26, 59.
- 18 A. . . . ., *J. China Pharm. Univ.* **1997**, 28, 271.
- 19 . . . . ., *China J. Chin. Mater. Med.* **2006**, 31, 41.
- 20 . . . . ., *Phytochemistry* **1996**, 41, 1319.
- 21 . . . . ., *Acta Pharmacol. Sin.* **1982**, 40, 273.
- 22 . . . . ., B. . . . ., *Bioorg. Med. Chem. Lett.* **1993**, 3, 1343.
- 23 . . . . ., *Bioorg. Med. Chem. Lett.* **2002**, 12, 3543.
- 24 T. . . . ., *Chem. Pharm. Bull.* **2007**, 55, 435.
- 25 . . . . ., *J. Nat. Prod.* **2007**, 70, 575.
- 26 . . . . ., C. . . . ., T. . . . ., *J. Mol. Med.* **1996**, 74, 583.
- 27 . . . . ., *J. Ethnopharmacol.* **2005**, 102, 424.
- 28 . . . . ., *J. Ethnopharmacol.* **2005**, 101, 31.
- 29 . . . . ., *Chem. Biodivers.* **2006**, 3, 754.
- 30 . . . . ., *Chem. Biodivers.* **2007**, 3, 967.
- 31 . . . . ., *Nat. Rev. Drug Discovery* **2002**, 1, 229.
- 32 . . . . ., *Int. Immunopharmacol.* **2005**, 5, 1.
- 33 A. . . . ., C. . . . ., *Drugs* **2007**, 67, 1167.
- 34 . . . . ., A. . . . ., *Vaccine* **1997**, 15, 48.
- 35 . . . . ., A. C. . . . ., A. . . . ., T. . . . ., *Biochem. Pharmacol.* **2004**, 68, 621.
- 36 . . . . ., *Org. Biomol. Chem.* **2006**, 4, 2483.

- 37 . . . . ., *Adv. Exp. Med. Biol.* **1998**, 439, 175.
- 38 . . A. . . . ., *Microcirculation* **2000**, 7, 29.
- 39 . . . . ., . . . . ., T. . . . ., . . . . ., . . . . ., *Chin. J. Exp. Tradit. Med. Formulae* **2006**, 12, 29.

*Received November 1, 2007*